{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:53Z","timestamp":1788174593255,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02674-8","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:03:37Z","timestamp":1751256217000},"page":"1838-1847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8938-3081","authenticated-orcid":false,"given":"Xiaoyuan","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-5541","authenticated-orcid":false,"given":"Wenbing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-207X","authenticated-orcid":false,"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0301","authenticated-orcid":false,"given":"Kaiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-7291","authenticated-orcid":false,"given":"Benfa","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0134-3849","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-0066","authenticated-orcid":false,"given":"Shaowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-8064","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-5070","authenticated-orcid":false,"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-3792","authenticated-orcid":false,"given":"Hui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2674_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547\u201355.","journal-title":"Lancet Oncol"},{"key":"2674_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","volume":"6","author":"G Martinelli","year":"2022","unstructured":"Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022;6:1742\u201353.","journal-title":"Blood Adv"},{"key":"2674_CR3","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2674_CR4","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u201334.","journal-title":"Lancet Haematol"},{"key":"2674_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"2674_CR6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"8","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8:1340\u20138.","journal-title":"JAMA Oncol"},{"key":"2674_CR7","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, et al. The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:2101\u201312.","journal-title":"Blood"},{"key":"2674_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"2674_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98:493\u2013501.","journal-title":"Am J Hematol"},{"key":"2674_CR10","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"2674_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Olverembatinib: first approval. Drugs. 2022;82:469\u201375.","journal-title":"Drugs"},{"key":"2674_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial. JAMA Oncol. 2025;11:28\u201335.","journal-title":"JAMA Oncol"},{"key":"2674_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00621-9","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang H, Yang C, Shi T, Zhang Y, Qian J, Wang Y, et al. Venetoclax-ponatinib for t315i\/compound-mutated ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12:20.","journal-title":"Blood Cancer J"},{"key":"2674_CR14","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","volume":"96","author":"NJ Short","year":"2021","unstructured":"Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96:E229\u201332.","journal-title":"Am J Hematol"},{"key":"2674_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/16078454.2020.1868783","volume":"26","author":"M Lyu","year":"2021","unstructured":"Lyu M, Jiang E, He Y, Yang D, Ma Q, Pang A, et al. Comparison of autologous and allogeneic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. 2021;26:65\u201374.","journal-title":"Hematology"},{"key":"2674_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2018.03.018","volume":"96","author":"S Giebel","year":"2018","unstructured":"Giebel S, Labopin M, Potter M, Poire X, Sengeloev H, Socie G, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: an analysis by the acute leukemia working party of the EBMT. Eur J Cancer. 2018;96:73\u201381.","journal-title":"Eur J Cancer"},{"key":"2674_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41409-022-01904-2","volume":"58","author":"S Giebel","year":"2023","unstructured":"Giebel S, Labopin M, Houhou M, Caillot D, Finke J, Blaise D, et al. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023;58:393\u2013400.","journal-title":"Bone Marrow Transplant"},{"key":"2674_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3324\/haematol.2013.085811","volume":"99","author":"M Wetzler","year":"2014","unstructured":"Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB study 10001 (Alliance). Haematologica. 2014;99:111\u20135.","journal-title":"Haematologica"},{"key":"2674_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/ijlh.14069","volume":"45","author":"L Wan","year":"2023","unstructured":"Wan L, Ma J, Gong X, Li Q, Wang Y, Wei H, et al. Droplet digital polymerase chain reaction improves the detection of BCR-ABL1 kinase domain mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Lab Hematol. 2023;45:528\u201332.","journal-title":"Int J Lab Hematol"},{"key":"2674_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00277-019-03594-1","volume":"98","author":"B Liu","year":"2019","unstructured":"Liu B, Wang Y, Zhou C, Wei H, Lin D, Li W, et al. Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up. Ann Hematol. 2019;98:633\u201345.","journal-title":"Ann Hematol"},{"key":"2674_CR21","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.clinthera.2021.05.009","volume":"43","author":"X Gong","year":"2021","unstructured":"Gong X, Li L, Wei H, Liu B, Zhou C, Zhang G, et al. A higher dose of dasatinib may increase the possibility of crossing the blood-brain barrier in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2021;43:1265\u201371.","journal-title":"Clin Ther"},{"key":"2674_CR22","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","volume":"55","author":"JC Kim","year":"2023","unstructured":"Kim JC, Chan-Seng-Yue M, Ge S, Zeng AGX, Ng K, Gan OI, et al. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. Nat Genet. 2023;55:1186\u201397.","journal-title":"Nat Genet"},{"key":"2674_CR23","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521\u20138.","journal-title":"Blood"},{"key":"2674_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-022-00265-2","volume":"11","author":"T Shi","year":"2022","unstructured":"Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X, et al. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Exp Hematol Oncol. 2022;11:13.","journal-title":"Exp Hematol Oncol"},{"key":"2674_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nm1253","volume":"11","author":"A Castor","year":"2005","unstructured":"Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11:630\u20137.","journal-title":"Nat Med"},{"key":"2674_CR26","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2674_CR27","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.24.00108","volume":"42","author":"R Kim","year":"2024","unstructured":"Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, et al. Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study. J Clin Oncol. 2024;42:3140\u201350.","journal-title":"J Clin Oncol"},{"key":"2674_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al. Ultrasensitive NGS MRD assessment in ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203.","journal-title":"Am J Hematol"},{"key":"2674_CR29","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel I, Bartels M, Duell J, Oberg H, Ussat S, Bruckmueller H, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017;130:2027\u201331.","journal-title":"Blood"},{"key":"2674_CR30","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gomez-Almaguer D, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. Jama. 2024;331:1814\u201323.","journal-title":"Jama"},{"key":"2674_CR31","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","volume":"6","author":"JM Ribera","year":"2022","unstructured":"Ribera JM, Garcia-Calduch O, Ribera J, Montesinos P, Cano-Ferri I, Martinez P, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022;6:5395\u2013402.","journal-title":"Blood Adv"},{"key":"2674_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with t315i-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022;15:113.","journal-title":"J Hematol Oncol"},{"key":"2674_CR33","doi-asserted-by":"publisher","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","volume":"8","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, et al. Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8:354ra114.","journal-title":"Sci Transl Med"},{"key":"2674_CR34","doi-asserted-by":"publisher","unstructured":"Shanmuganathan N, Grigg A. A critical review of management of allogeneic transplant-eligible adults with ph+ acute lymphoblastic leukaemia. Br J Haematol 2024. https:\/\/doi.org\/10.1111\/bjh.19682.","DOI":"10.1111\/bjh.19682"},{"key":"2674_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000539391","volume":"47","author":"F Lang","year":"2024","unstructured":"Lang F, Pfeifer H, Bruggemann M, Hermann E, Serve H, Goekbuget N. A multicentre, randomized trial in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukaemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for stem cell transplantation versus tyrosine kinase inhibitor, blinatumomab, and chemotherapy in optimal responders, and to evaluate blinatumomab in suboptimal responders (GMALL-EVOLVE). Oncol Res Treat. 2024;47:430\u20133.","journal-title":"Oncol Res Treat"}],"updated-by":[{"DOI":"10.1038\/s41375-025-02696-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02674-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:12:39Z","timestamp":1757063559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02674-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2674"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02674-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The name of co-author Dr. Wenbing Liu was inadvertently misspelled as \u201cWenbin Liu\u201d. The correct spelling should be \u201cWenbing Liu\u201d. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02696-2","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02696-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethics committee of the Institute of Hematology and Blood Diseases Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consents were obtained for this study and the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}